SAFETY AND TOLERABILITY OF DORIPENEM IN HOSPITALIZED CHILDREN WITH COMPLICATED INTRA-ABDOMINAL INFECTION, COMPLICATED URINARY TRACT INFECTIONS AND PNEUMONIA

被引：9

作者：

Cannavino, Christopher R. ^{[1
,2
]}

Castaneda-Ruiz, Bibiana ^{[3
]}

Redman, Rebecca ^{[3
]}

Go, Oscar ^{[4
]}

Cirillo, Iolanda ^{[5
]}

Barauskas, Vidmantas ^{[6
]}

Senatorova, Ganna ^{[7
]}

Emeryk, Andrzej ^{[8
]}

Bradley, John S. ^{[1
]}

机构：

[1] Univ Calif San Diego, Div Infect Dis, Dept Pediat, La Jolla, CA 92093 USA

[2] Rady Childrens Hosp, San Diego, CA USA

[3] Janssen Pharmaceut Companies Johnson & Johnson, Infect Dis & Vaccines, Raritan, NJ USA

[4] Janssen Pharmaceut Companies Johnson & Johnson, Stat & Decis Sci, Raritan, NJ USA

[5] Janssen Pharmaceut Companies Johnson & Johnson, Clin Pharmacol, Raritan, NJ USA

[6] Lithuanian Univ Hlth Sci, Dept Pediat Surg, Kaunas, Lithuania

[7] Kharkiv Natl Med Univ, Dept Pediat & Neonatol 1, Kharkov, Ukraine

[8] Med Univ Lublin, Poland Univ Childrens Hosp, Dept Lung Dis & Pediat Rheumatol, Lublin, Poland

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2015年 / 34卷 / 11期

关键词：

doripenem; children; complicated urinary tract infection; complicated intra-abdominal infection; pneumonia; INTRAVENOUS DORIPENEM; EFFICACY; PYELONEPHRITIS; MULTICENTER; MEROPENEM; THERAPY;

D O I：

10.1097/INF.0000000000000859

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Three multicenter, randomized, controlled studies evaluated doripenem in children 3 months to <18 years of age, with complicated intra-abdominal or urinary tract infections and bacterial pneumonia. In the 66 patients treated with doripenem before early termination of the studies for nonsafety reasons, doripenem was safe and generally well tolerated. Low enrollment limited ability to assess benefits and risks of doripenem in children.

引用

页码：1264 / 1267

页数：4

共 8 条

[1] Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients
Bradley, JS
Faulkner, KL
[J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (08) : 749 - 757
[2] Pharmacokinetics, Safety, and Tolerability of Doripenem After 0.5-, 1-, and 4-Hour Infusions in Healthy Volunteers
Cirillo, Iolanda
Vaccaro, Nicole
Turner, Kenneth
Solanki, Bhavna
Natarajan, Jaya
Redman, Rebecca
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (07) : 798 - 806
[3] Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study
Lucasti, Christopher
Jasovich, Abel
Umeh, Obiarnivve
Jiang, Joel
Kaniga, Kone
Friedland, Ian
[J]. CLINICAL THERAPEUTICS, 2008, 30 (05) : 868 - 883
[4] Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis
Naber, K. G.
Llorens, L.
Kaniga, K.
Kotey, P.
Hedrich, D.
Redman, R.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (09) : 3782 - 3792
[5] Population Pharmacokinetics of Doripenem Based on Data from Phase 1 Studies with Healthy Volunteers and Phase 2 and 3 Studies with Critically Ill Patients
Nandy, Partha
Samtani, Mahesh N.
Lin, Rachel
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) : 2354 - 2359
[6] Réa-Neto A, 2008, CURR MED RES OPIN, V24, P2113, DOI [10.1185/03007990802179255, 10.1185/03007990802179255 ]
[7] Safety and Efficacy of Intravenous Doripenem for the Treatment of Complicated Urinary Tract Infections and Pyelonephritis
Redman, R.
Damiao, R.
Kotey, P.
Kaniga, K.
Davies, T.
Naber, K. G.
[J]. JOURNAL OF CHEMOTHERAPY, 2010, 22 (06) : 384 - 391
[8] In Vitro Activity of Doripenem
Sahm, Daniel
[J]. CLINICAL INFECTIOUS DISEASES, 2009, 49 : S11 - S16

← 1 →